Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) announced that Thomas A. Ciulla, M.D., CMO, will present at two virtual conferences in April 2021. The first is the Needham Virtual Healthcare Conference on April 12 at 12:45 p.m. ET, with live access on their website. The second is the Wet AMD & DME Drug Development Summit on April 14, featuring discussions on treatment burdens and innovative drug delivery solutions for serious eye diseases. Clearside focuses on therapies to restore vision and utilizes its proprietary SCS Microinjector for targeted drug delivery.

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021:

Needham Virtual Healthcare Conference
Monday, April 12, 2021 at 12:45 p.m. ET

• The live and archived Needham Virtual Healthcare Conference presentation webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.
  

Wet AMD & DME Drug Development Summit
Wednesday, April 14, 2021
Event details are available on the conference website.

• 10:45 a.m. ET - Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics
• 1:40 p.m. ET - Suprachoroidal Drug Delivery & CLS-AX: A Potential Solution for Treatment Burden
• 2:55 p.m. ET - Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing
  

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector^® targeting the suprachoroidal space (SCS^®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

 

FAQ

When is Clearside Biomedical presenting at the Needham Virtual Healthcare Conference?

Clearside Biomedical will present at the Needham Virtual Healthcare Conference on April 12, 2021, at 12:45 p.m. ET.

What topics will Clearside Biomedical cover at the Wet AMD & DME Drug Development Summit?

At the Wet AMD & DME Drug Development Summit on April 14, 2021, Clearside Biomedical will discuss treatment burdens and potential solutions involving suprachoroidal drug delivery.

Where can I access the presentation from the Needham Virtual Healthcare Conference?

The presentation can be accessed live and archived on the Clearside website under the Investors section.

What is the focus of Clearside Biomedical's research?

Clearside Biomedical focuses on developing treatments that restore and preserve vision for individuals with serious back of the eye diseases.